Miller K D, Sledge G W
Indiana University School of Medicine, Indianapolis, Indiana, USA.
Cancer Invest. 1999;17(2):121-36.
The taxanes, paclitaxel and docetaxel, are among the most promising new agents in the treatment of breast cancer. Responses are routinely seen in > 30% of patients with metastatic disease, including those who have previously received anthracyclines. Combination therapy has increased response rates but as yet has not improved the overall survival of patients with metastatic disease. Improved survival with the addition of paclitaxel to standard adjuvant therapy reported in a recently completed trial suggests the true impact of the taxanes has not yet been realized.
紫杉烷类药物，即紫杉醇和多西他赛，是治疗乳腺癌最有前景的新型药物之一。转移性疾病患者中通常有超过30%会出现反应，包括那些之前接受过蒽环类药物治疗的患者。联合治疗提高了反应率，但尚未改善转移性疾病患者的总体生存率。最近完成的一项试验报告显示，在标准辅助治疗中添加紫杉醇可提高生存率，这表明紫杉烷类药物的真正影响尚未完全显现。
